Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.
So far, there are no means of identifying rheumatoid arthritis (RA) patients who will fail to respond to tumour necrosis factor blocking agents (anti-TNF), prior to treatment. We set out to validate eight previously reported gene expression signatures predicting therapy outcome. Genome-wide expressi...
Guardado en:
Autores principales: | Erik J M Toonen, Christian Gilissen, Barbara Franke, Wietske Kievit, Agnes M Eijsbouts, Alfons A den Broeder, Simon V van Reijmersdal, Joris A Veltman, Hans Scheffer, Timothy R D J Radstake, Piet L C M van Riel, Pilar Barrera, Marieke J H Coenen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f82ca101767b4a1f92e2ffe26a4e189b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A replication study of the association between rheumatoid arthritis and deletion of the late cornified envelope genes LCE3B and LCE3C.
por: Judith G M Bergboer, et al.
Publicado: (2012) -
TNF, SOLUBLE RECEPTORS AND AUTOANTIBODIES TO TNF OF PATIENTS WITH RHEUMATOID ARTHRITIS AND HEALTHY DONORS
por: E. A. Golikova, et al.
Publicado: (2012) -
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow J, et al.
Publicado: (2012) -
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Borja Hernández-Breijo, et al.
Publicado: (2021) -
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
por: Kalle J Aaltonen, et al.
Publicado: (2012)